Project Grant HT9425261E278
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- This federal Project Grant award of $678,000.00 was issued on July 1, 2024 by the Defense Health Agency, under the CFDA 12.420 Military Medical Research and Development program, to Rockefeller University. The funding supports a 2-year research project titled "Finding Therapeutic Vulnerabilities in an AYA Cancer with CRISPR/Cas9". The project aims to conduct innovative biomedical research focused on improving health outcomes for military service members, veterans, and the broader...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Columbia University's Health Sciences Division a $750,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through June 30, 2029. The award supports research to identify and validate novel therapeutic targets designed to overcome treatment resistance in triple-negative breast cancer (TNBC). This research initiative aligns with the program's strategic focus on...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary The University of Rochester received a $1.65M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded May 1, 2026, with completion targeted for April 30, 2029. The award funds research and development activities centered on CAR (Chimeric Antigen Receptor)-dendritic cell engineering as a targeted therapeutic delivery platform for tumor necrosis factor-alpha (TNF-alpha) in breast cancer...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $1,145,096 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The grant supports research to develop modeling approaches and targeting strategies for FH-deficient renal cell carcinoma with the objective of advancing precision therapy options. This research initiative aligns with the DHA's...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...
- Federal Grant Award Summary New York University School of Medicine received a $1.35M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on June 15, 2026, with performance through June 14, 2029. The award supports research investigating neoadjuvant checkpoint and interleukin-6 (IL-6) blockade therapies, with specific focus on elucidating the mechanisms underlying clinical benefit and toxicity profiles of these...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.25 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026 through April 30, 2029. This research award supports the development of first-in-class protein degraders targeting oncogenic PTK6 (protein tyrosine kinase 6) in triple-negative breast cancer, a particularly aggressive form of breast cancer with limited therapeutic...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research At Roswell Park) received a $958,389 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2030. This four-year award supports hypothesis-driven biomedical research initiatives aligned with the DHA's mission to transform healthcare for service members and the American public through innovative medical...